Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (44) 44
science & technology (42) 42
life sciences & biomedicine (41) 41
oncology (34) 34
female (31) 31
male (30) 30
aged (24) 24
middle aged (24) 24
biological and medical sciences (23) 23
medical sciences (22) 22
adult (21) 21
tumors (19) 19
aged, 80 and over (16) 16
imatinib mesylate (15) 15
benzamides (14) 14
cancer (12) 12
gastroenterology. liver. pancreas. abdomen (11) 11
abridged index medicus (10) 10
antineoplastic agents - therapeutic use (10) 10
chemotherapy (10) 10
disease-free survival (10) 10
stomach. duodenum. small intestine. colon. rectum. anus (10) 10
survival rate (10) 10
treatment outcome (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
gastrointestinal stromal tumors - drug therapy (9) 9
piperazines - therapeutic use (9) 9
pyrimidines - therapeutic use (9) 9
follow-up studies (8) 8
medicine & public health (8) 8
mutation (8) 8
prognosis (8) 8
proto-oncogene proteins c-kit - genetics (8) 8
gastrointestinal stromal tumors - genetics (7) 7
gastrointestinal stromal tumors - pathology (7) 7
general & internal medicine (7) 7
medicine, general & internal (7) 7
neoplasm metastasis (7) 7
adolescent (6) 6
care and treatment (6) 6
clinical trials (6) 6
young adult (6) 6
chemotherapy, adjuvant (5) 5
colorectal cancer (5) 5
fluorouracil - administration & dosage (5) 5
gastrointestinal stromal tumors - mortality (5) 5
gastrointestinal stromal tumors - surgery (5) 5
neoplasm recurrence, local - drug therapy (5) 5
receptor, platelet-derived growth factor alpha - genetics (5) 5
antineoplastic agents (4) 4
antineoplastic agents - adverse effects (4) 4
cancer therapies (4) 4
colorectal neoplasms - drug therapy (4) 4
combined modality therapy (4) 4
hematology, oncology and palliative medicine (4) 4
lung neoplasms - drug therapy (4) 4
medical research (4) 4
neoplasm recurrence, local - surgery (4) 4
neoplasm staging (4) 4
neurosciences & neurology (4) 4
retrospective studies (4) 4
surgery (4) 4
survival analysis (4) 4
adenocarcinoma - mortality (3) 3
analysis (3) 3
antineoplastic agents - administration & dosage (3) 3
clinical trials as topic (3) 3
colorectal neoplasms - pathology (3) 3
diagnosis (3) 3
fluorouracil - adverse effects (3) 3
gastroenterology and hepatology (3) 3
gastrointestinal neoplasms - drug therapy (3) 3
gastrointestinal tumors (3) 3
general aspects (3) 3
irinotecan (3) 3
leucovorin - administration & dosage (3) 3
metastasis (3) 3
national cancer institute (3) 3
neoplasm recurrence, local - pathology (3) 3
neoplasms (3) 3
patients (3) 3
pharmacology. drug treatments (3) 3
piperazines - administration & dosage (3) 3
piperazines - adverse effects (3) 3
prospective studies (3) 3
protein kinase inhibitors - therapeutic use (3) 3
protein-tyrosine kinases - antagonists & inhibitors (3) 3
proto-oncogene proteins c-kit - metabolism (3) 3
pyrimidines - administration & dosage (3) 3
pyrimidines - adverse effects (3) 3
radiotherapy (3) 3
research (3) 3
studies (3) 3
surgical oncology (3) 3
surveys and questionnaires (3) 3
5-fluorouracil (2) 2
adenocarcinoma - drug therapy (2) 2
adenocarcinoma - pathology (2) 2
adenocarcinoma - therapy (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
by DeMatteo, Ronald P, Prof and Ballman, Karla V, PhD and Antonescu, Cristina R, MD and Maki, Robert G, MD and Pisters, Peter WT, Prof and Demetri, George D, MD and Blackstein, Martin E, MD and Blanke, Charles D, Prof and von Mehren, Margaret, MD and Brennan, Murray F, Prof and Patel, Shreyaskumar, Prof and McCarter, Martin D, MD and Polikoff, Jonathan A, MD and Tan, Benjamin R, MD and Owzar, Kouros, PhD and on behalf of the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team and ACOSOG Intergrp Adjuvant GIST Stud and American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team
The Lancet (British edition), ISSN 0140-6736, 2009, Volume 373, Issue 9669, pp. 1097 - 1104
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Biological and medical sciences | General aspects | Medical sciences | Tumors | Piperazines - administration & dosage | Gastrointestinal Stromal Tumors - surgery | Double-Blind Method | Pyrimidines - administration & dosage | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Imatinib Mesylate | Piperazines - adverse effects | Gastrointestinal Stromal Tumors - therapy | Antineoplastic Agents - adverse effects | Gastrointestinal Stromal Tumors - pathology | Adolescent | Pyrimidines - adverse effects | Aged, 80 and over | Adult | Female | Aged | Benzamides | Chemotherapy, Adjuvant | Gastrointestinal Stromal Tumors - mortality | Care and treatment | Research | Gastrointestinal tumors | Patient outcomes | Studies | Physical examinations | Chemotherapy | Health services | Medical treatment | Patient care planning | Oncology | Mutation | Small intestine | Patients | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Impact of the Year 2000 Medicare Policy Change on Older Patient Enrollment to Cancer Clinical Trials
by Joseph M. Unger and Charles A. Coltman Jr and John J. Crowley and Laura F. Hutchins and Silvana Martino and Robert B. Livingston and John S. Macdonald and Charles D. Blanke and David R. Gandara and E. David Crawford and Kathy S. Albain
Journal of clinical oncology, ISSN 0732-183X, 01/2006, Volume 24, Issue 1, pp. 141 - 144
Biological and medical sciences | Medical sciences | Tumors | Neoplasms - therapy | Medicare | Neoplasms - ethnology | Humans | Female | Male | Aged | Clinical Trials as Topic | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
by Charles D. Blanke and George D. Demetri and Margaret von Mehren and Michael C. Heinrich and Burton Eisenberg and Jonathan A. Fletcher and Christopher L. Corless and Christopher D.M. Fletcher and Peter J. Roberts and Daniela Heinz and Elisabeth Wehre and Zariana Nikolova and Heikki Joensuu
Journal of clinical oncology, ISSN 0732-183X, 02/2008, Volume 26, Issue 4, pp. 620 - 625
Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Biological and medical sciences | Medical sciences | Tumors | Piperazines - administration & dosage | Multivariate Analysis | Neutrophils - cytology | Prospective Studies | Humans | Male | Antineoplastic Agents - administration & dosage | Proto-Oncogene Proteins c-kit - metabolism | Female | Proto-Oncogene Proteins c-kit - genetics | Leukocyte Count | Gastrointestinal Stromal Tumors - mortality | Gastrointestinal Stromal Tumors - genetics | Receptor, Platelet-Derived Growth Factor alpha - metabolism | Albumins - metabolism | Pyrimidines - administration & dosage | Survival Rate | Imatinib Mesylate | Disease Progression | Disease-Free Survival | Gastrointestinal Stromal Tumors - drug therapy | Receptor, Platelet-Derived Growth Factor alpha - genetics | Aged | Benzamides | Mutation | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414)
by Tomblyn, Michael B and Goldman, Bryan H and Thomas, Charles R and Benedetti, Jacqueline K and Lenz, Heinz-Josef and Mehta, Vivek and Beeker, Thaddeus and Gold, Philip J and Abbruzzese, James L and Blanke, Charles D and for the SWOG GI Committee and SWOG GI Comm and SWOG GI Committee
Journal of thoracic oncology, ISSN 1556-0864, 05/2012, Volume 7, Issue 5, pp. 906 - 912
Irinotecan | Cetuximab | Radiotherapy | Esophageal | Cisplatin | Respiratory System | Oncology | Life Sciences & Biomedicine | Science & Technology | Adenocarcinoma - pathology | Prognosis | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Male | Chemoradiotherapy | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Antibodies, Monoclonal, Humanized | Thoracic Neoplasms - radiotherapy | Carcinoma, Squamous Cell - mortality | Aged, 80 and over | Esophageal Neoplasms - mortality | Adult | Camptothecin - administration & dosage | Female | Esophageal Neoplasms - therapy | Camptothecin - analogs & derivatives | Carcinoma, Squamous Cell - therapy | Survival Rate | Remission Induction | Thoracic Neoplasms - mortality | Adenocarcinoma - therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Thoracic Neoplasms - drug therapy | Neoplasm Staging | Adenocarcinoma - mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
by Charles D. Blanke and Cathryn Rankin and George D. Demetri and Christopher W. Ryan and Margaret von Mehren and Robert S. Benjamin and A. Kevin Raymond and Vivien H.C. Bramwell and Laurence H. Baker and Robert G. Maki and Michael Tanaka and J. Randolph Hecht and Michael C. Heinrich and Christopher D.M. Fletcher and John J. Crowley and Ernest C. Borden
Journal of clinical oncology, ISSN 0732-183X, 02/2008, Volume 26, Issue 4, pp. 626 - 632
Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Biological and medical sciences | Medical sciences | Tumors | Piperazines - administration & dosage | Prognosis | Follow-Up Studies | Pyrimidines - administration & dosage | Humans | Middle Aged | Male | Survival Rate | Proto-Oncogene Proteins c-kit - metabolism | Imatinib Mesylate | Disease-Free Survival | Gastrointestinal Stromal Tumors - drug therapy | Gastrointestinal Stromal Tumors - pathology | Aged, 80 and over | Adult | Female | Aged | Retrospective Studies | Benzamides | Gastrointestinal Stromal Tumors - mortality | Gastrointestinal Stromal Tumors - genetics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Microscopically Positive Margins for Primary Gastrointestinal Stromal Tumors: Analysis of Risk Factors and Tumor Recurrence
by McCarter, Martin D., MD, FACS and Antonescu, Cristina R., MD and Ballman, Karla V., PhD and Maki, Robert G., MD, PhD and Pisters, Peter W.T., MD, FACS and Demetri, George D., MD and Blanke, Charles D., MD and von Mehren, Margaret, MD and Brennan, Murray F., MD, FACS and McCall, Linda, MS and Ota, David M., MD, FACS and DeMatteo, Ronald P., MD, FACS and American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant Gist Study Team
Journal of the American College of Surgeons, ISSN 1072-7515, 2012, Volume 215, Issue 1, pp. 53 - 59
Surgery | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Biological and medical sciences | General aspects | Medical sciences | Tumors | Gastrointestinal Stromal Tumors - surgery | Humans | Middle Aged | Risk Factors | Male | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Imatinib Mesylate | Young Adult | Pyrimidines - therapeutic use | Gastrointestinal Stromal Tumors - pathology | Adolescent | Aged, 80 and over | Adult | Female | Aged | Neoplasm Recurrence, Local - epidemiology | Benzamides | Medical colleges | Research | Oncology, Experimental | Risk factors | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
by Michael C. Heinrich and Kouros Owzar and Christopher L. Corless and Donna Hollis and Ernest C. Borden and Christopher D.M. Fletcher and Christopher W. Ryan and Margaret von Mehren and Charles D. Blanke and Cathryn Rankin and Robert S. Benjamin and Vivien H. Bramwell and George D. Demetri and Monica M. Bertagnolli and Jonathan A. Fletcher
Journal of clinical oncology, ISSN 0732-183X, 11/2008, Volume 26, Issue 33, pp. 5360 - 5367
Life Sciences & Biomedicine | Oncology | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Biological and medical sciences | Medical sciences | Tumors | Humans | Genotype | Survival Rate | Piperazines - therapeutic use | Imatinib Mesylate | Disease-Free Survival | Gastrointestinal Stromal Tumors - drug therapy | Pyrimidines - therapeutic use | Receptor, Platelet-Derived Growth Factor alpha - genetics | Gastrointestinal Stromal Tumors - pathology | Proto-Oncogene Proteins c-kit - genetics | Benzamides | Gastrointestinal Stromal Tumors - mortality | Mutation | Gastrointestinal Stromal Tumors - genetics | Index Medicus | Sarcomas
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
by Michael C. Heinrich and Christopher L. Corless and Charles D. Blanke and George D. Demetri and Heikki Joensuu and Peter J. Roberts and Burton L. Eisenberg and Margaret von Mehren and Christopher D.M. Fletcher and Katrin Sandau and Karen McDougall and Wen-bin Ou and Chang-Jie Chen and Jonathan A. Fletcher
Journal of clinical oncology, ISSN 0732-183X, 10/2006, Volume 24, Issue 29, pp. 4764 - 4774
Life Sciences & Biomedicine | Oncology | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Biological and medical sciences | Medical sciences | Tumors | Humans | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Platelet-Derived Growth Factor - genetics | Drug Resistance, Neoplasm - genetics | RNA Interference | Gastrointestinal Stromal Tumors - drug therapy | Proto-Oncogene Proteins c-kit - genetics | Antineoplastic Agents - pharmacology | Benzamides | Gastrointestinal Stromal Tumors - genetics | Cohort Studies | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
by Patel, Sandip P and Othus, Megan and Chae, Young Kwang and Giles, Francis J and Hansel, Donna E and Singh, Preet Paul and Fontaine, Annette and Shah, Manisha and Kasi, Anup and Al Baghdadi, Tareq and Matrana, Marc and Gatalica, Zoran and Korn, W. Michael and Hayward, Jourdain and McLeod, Christine and Chen, Helen X and Sharon, Elad and Mayerson, Edward and Ryan, Christopher W and Plets, Melissa and Blanke, Charles and Kurzrock, Razelle
Clinical cancer research, ISSN 1078-0432, 05/2020, Volume 26, Issue 10, pp. 2290 - 2296
Life Sciences & Biomedicine | Oncology | Science & Technology | Neuroendocrine Tumors - pathology | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Rare Diseases - drug therapy | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Survival Rate | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Neuroendocrine Tumors - drug therapy | Adult | Female | Rare Diseases - pathology | Aged | CTLA-4 Antigen - antagonists & inhibitors | Ipilimumab - administration & dosage | Nivolumab - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
by Michael C. Heinrich and Christopher L. Corless and George D. Demetri and Charles D. Blanke and Margaret von Mehren and Heikki Joensuu and Laura S. McGreevey and Chang-Jie Chen and Annick D. Van den Abbeele and Brian J. Druker and Beate Kiese and Burton Eisenberg and Peter J. Roberts and Samuel Singer and Christopher D.M. Fletcher and Sandra Silberman and Sasa Dimitrijevic and Jonathan A. Fletcher
Journal of clinical oncology, ISSN 0732-183X, 12/2003, Volume 21, Issue 23, pp. 4342 - 4349
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Tumors | Gastrointestinal Neoplasms - secondary | Phosphorylation | Gastrointestinal Neoplasms - genetics | Prognosis | Exons | Gastrointestinal Neoplasms - drug therapy | Stromal Cells - pathology | Humans | Gene Expression Regulation, Neoplastic | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Proto-Oncogene Proteins c-kit - metabolism | Immunoenzyme Techniques | Transfection | DNA Mutational Analysis | Proto-Oncogene Proteins c-kit - genetics | CHO Cells | Cricetinae | Mutagenesis, Site-Directed | Receptor, Platelet-Derived Growth Factor alpha - metabolism | Survival Rate | Piperazines - therapeutic use | Imatinib Mesylate | Animals | Pyrimidines - therapeutic use | Receptor, Platelet-Derived Growth Factor alpha - genetics | Benzamides | DNA, Neoplasm - genetics | Mutation | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report
by Bertagnolli, Monica M and Blanke, Charles D and Curran, Walter J and Hawkins, Douglas S and Mannel, Robert S and O’Dwyer, Peter J and Schnall, Mitchell D and Wolmark, Norman
Cancer, ISSN 0008-543X, 12/2020, Volume 126, Issue 23, pp. 5022 - 5029
National Cancer Institute (NCI) | cooperative groups | NCI National Clinical Trials Network (NCTN) | cancer clinical trials | NCI Community Oncology Research Program (NCORP) | Life Sciences & Biomedicine | Oncology | Science & Technology | Clinical trials | Biomarkers | Halloween | Funding | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Phase II Trial of Erlotinib in Gastroesophageal Junction and Gastric Adenocarcinomas: SWOG 0127
by Tomislav Dragovich and Sheryl McCoy and Cecilia M. Fenoglio-Preiser and Jiang Wang and Jacqueline K. Benedetti and Amanda F. Baker and Christopher B. Hackett and Susan G. Urba and Ken S. Zaner and Charles D. Blanke and James L. Abbruzzese
Journal of clinical oncology, ISSN 0732-183X, 10/2006, Volume 24, Issue 30, pp. 4922 - 4927
Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Biological and medical sciences | Medical sciences | Tumors | Erlotinib Hydrochloride | Predictive Value of Tests | Humans | Middle Aged | Stomach Neoplasms - metabolism | Male | Treatment Outcome | Stomach Neoplasms - drug therapy | Esophagogastric Junction | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Esophageal Neoplasms - metabolism | Survival Analysis | Biomarkers, Tumor - metabolism | Female | Esophageal Neoplasms - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials
by Daniel J. Sargent and Harry S. Wieand and Daniel G. Haller and Richard Gray and Jacqueline K. Benedetti and Marc Buyse and Roberto Labianca and Jean Francois Seitz and Christopher J. O'Callaghan and Guido Francini and Axel Grothey and Michael O'Connell and Paul J. Catalano and Charles D. Blanke and David Kerr and Erin Green and Norman Wolmark and Thierry Andre and Richard M. Goldberg and Aimery De Gramont
Journal of clinical oncology, ISSN 0732-183X, 12/2005, Volume 23, Issue 34, pp. 8664 - 8670
Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Biological and medical sciences | Medical sciences | Tumors | Follow-Up Studies | Colonic Neoplasms - drug therapy | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Treatment Outcome | Combined Modality Therapy | Neoplasm Recurrence, Local - surgery | Randomized Controlled Trials as Topic | Colonic Neoplasms - surgery | Disease-Free Survival | Regression Analysis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Female | Aged | Chemotherapy, Adjuvant | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405
by Guercio, Brendan J and Zhang, Sui and Ou, Fang-Shu and Venook, Alan P and Niedzwiecki, Donna and Lenz, Heinz-Josef and Innocenti, Federico and O'Neil, Bert H and Shaw, James E and Polite, Blase N and Hochster, Howard S and Atkins, James N and Goldberg, Richard M and Sato, Kaori and Ng, Kimmie and Van Blarigan, Erin and Mayer, Robert J and Blanke, Charles D and O'Reilly, Eileen M and Fuchs, Charles S and Meyerhardt, Jeffrey A
Journal of clinical oncology, ISSN 0732-183X, 10/2019, Volume 37, Issue 29, pp. 2620 - 2631
Life Sciences & Biomedicine | Oncology | Science & Technology | Index Medicus | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow